Close

BIO Statement on USDA Withdrawal of 340 Biotech Rules

Nov 6 2017
The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) today announced its intention to withdraw its proposed revisions to regulations (7 CFR part 340) governing agricultural biotechnology.  The Biotechnology Innovation Organization (BIO) issued the following statement in response:

BIO Releases Plan to Unleash Innovation in Fight against Opioid Abuse and Addiction

Nov 2 2017
Washington, DC (November 2, 2017) – The Biotechnology Innovation Organization (BIO) today released a set of priorities for unleashing the power of innovation to develop solutions to prescription opioid abuse and addiction. Many of BIO’s priorities align with recommendations put forth yesterday by the President’s Commission on Combating Drug Addiction and the Opioid Crisis, including proposals to ensure that patients have comprehensive access to appropriate treatments, and increasing support for basic research to improve our understanding of the biology of pain and addiction. 

BIO Statement on House GOP Tax Reform Bill

Nov 2 2017
Washington, DC (November 2, 2017) – Biotechnology Innovation Organization (BIO) Jim Greenwood released the following statement today regarding the Tax Cuts and Jobs Act: “BIO applauds Chairman Brady and the House Ways & Means Committee for their dedication to pro-growth tax reform. Tax reform presents a unique, historic opportunity to stimulate American investment, support job creation, and promote life-saving innovation. The Tax Cuts and Jobs Act would lower America’s corporate tax rate, maintain the R&D Tax Credit, and move the U.S. to a territorial tax system, which will make the U.S. more competitive on the world stage and support domestic manufacturing and job creation. This reform is vital to maintaining American leadership in biotechnology innovation.

BIO Applauds MLP Parity Act, Thanks Senate and House Sponsors

Oct 25 2017
The bipartisan Master Limited Partnerships Parity Act of 2017 would level the playing field in the tax code by giving investors in renewable energy projects access to a decades-old corporate structure with a tax advantage now available only to fossil fuel projects.

BIO, Member Companies Ask Congress to Reauthorize Section 9003 Program in Farm Bill

Oct 19 2017
BIO and 66 renewable chemical producers today asked leaders of the House and Senate Committees on Agriculture to reauthorize the Farm Bill’s Biorefinery, Renewable Chemical, and Biobased Manufacturing Assistance Program (Section 9003) and “fully and unconditionally allow renewable chemical standalone manufacturing facilities” to receive Section 9003 Program loan guarantees without requiring production of advanced biofuels.

BIO Applauds Senate Introduction of Renewable Chemicals Tax Credit

Oct 19 2017
BIO thanks Sen. Debbie Stabenow (D-MI) and co-sponsors Sens. Tammy Baldwin (D-WI), Susan Collins (R-ME), Chris Coons (D-DE), and Al Franken (D-MN) for introducing the Renewable Chemicals Act of 2017 (S.1980), which would create a targeted, short-term tax credit for production of qualifying renewable chemicals or investment in production facilities.

BIO Investor Forum Concludes

Oct 18 2017
The BIO Investor Forum finished today after hosting two days of expert-led panel discussions, fireside chats, over 165 company presentations and more than 2,750 individual meetings arranged through BIO One-on-One Partnering — a 26 percent increase over last year. The event was attended by more than 1,000 representatives of private and early stage biotech companies, leading investment firms, research organizations and others who came together to foster the development of new medical treatments and to grow the industry’s pipeline. 

Hill Leaders Urge Support for Reg System that Supports Ag Innovation

Oct 17 2017
USDA, FDA and EPA must “coordinate with each other and stakeholders”  Washington, D.C. (October 17, 2017) – Under the leadership of Reps. Neal Dunn (R-Fla.) and Jimmy Panetta (D-Calif.), 79 Members of the House of Representatives signed on to a letter urging for a “consistent, science-based, risk-proportionate regulatory system” for agricultural biotechnology.

BIO Statement on California Governor Brown Signing Drug Price Reporting & Transparency Bill

Oct 9 2017
BIO will continue to oppose legislative efforts, such as SB 17, that harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through misguided government intrusion.

BIO Congratulates SAB Biotherapeutics on Pharm Groundbreaking

Oct 5 2017
Sioux Falls, S.D. 80-acre biological pharm is first-of-its kind   Washington, D.C. (October 5, 2017) – Sioux Falls, S.D.-based SAB Biotherapeutics, Inc. (SAB), celebrated construction of their 80-acre biopharmaceutical production pharm operation with a groundbreaking ceremony today in Lincoln County.